Catalyst Pharmaceutical Partners licenses exclusive rights to new class of GABA aminotransferase inhibitors from Northwestern University.

Catalyst Pharmaceutical Partners Inc (Catalyst Pharmaceutical) announced that the company executed a licence agreement under which it acquired exclusive worldwide rights to commercialize novel GABA aminotransferase inhibitors and derivatives of vigabatrin discovered by Northwestern University. These compounds may have applications to a broad range of neurological diseases, including addiction and epilepsy. Catalyst Pharmaceutical intends to pursue development work on an undisclosed, lead oral compound that has already been identified. Under the terms of the agreement, Northwestern University granted Catalyst an exclusive worldwide licence to certain composition of matter patents related …